Duloxetine Delayed-Release Capsules
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
Recalls of antidepressants, anti-anxiety and related psychiatric medications.
224 recalls in this category, newest first.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled as 0.125 mg instead of 0.25 mg. The blister strips inside the product carton reflect the correct strength of 0.25 mg.
Failed Dissolution Specifications; the product is dissolving faster than the specified limits.
Failed Dissolution Specifications: Out-of-specification results observed for dissolution testing at the 8-hour and 12-hour pull intervals.
Failed dissolution specifications: out of specification result obtained during routine stability testing for high dissolution.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Presence of Foreign Tablets/Capsules
CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.
Failed Dissolution Specifications
Failed Dissolution Specifications
CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.
CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.
CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.
CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.
CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.
CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.
CGMP Deviations: Potential risk of Cross Contamination
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.